-
How should traditional Chinese medicine companies spin off traditional Chinese medicines and transform them?
Time of Update: 2021-04-27
On March 22, Livzon Pharmaceutical announced that it plans to acquire 40% of Tianjin Tongrentang held by Tasly Holding Group as a financial investor for 724 million yuan.
-
Boehringer Ingelheim's new drug BI 425809 for schizophrenia received clinical approval
Time of Update: 2021-04-27
The primary end point was the change from baseline in the patient's overall MCCB overall T-score (consensus version of the schizophrenia cognitive function test suite, a neurocognitive efficacy assessment test for schizophrenia) at the 12th week.
-
The Liaoning Provincial Food and Drug Administration issued a public solicitation of opinions on the preparation of four Chinese herbal medicines including yew
Time of Update: 2021-04-27
On March 24, the Liaoning Provincial Food and Drug Administration issued an announcement on publicly soliciting opinions on the processing standards of four Chinese herbal medicines including yew.
-
Novo Nordisk's high-dose semaglutide treatment application for diabetes is rejected by the FDA
Time of Update: 2021-04-27
0 mg once a week for treatment 2 Application for label extension for type-diabetes.
Although more information needs to be included in the resubmission, Novo Nordisk stated that the company believes that the completed clinical trial projects are sufficient to support semaglutide's label extension application.
-
Dongyang Sunshine's "Entacapone Film" Approved for Listing
Time of Update: 2021-04-27
Recently, the official website of the State Food and Drug Administration showed that the entacapone tablets declared by Dongyang Sunshine according to registration classification 4 have been approved for marketing by NMPA (approval number: National Medicine Standard H20213207).
-
Consumables in the eight regions of Henan have been bargained to start mass production
Time of Update: 2021-04-27
Medical Network News on March 25 Bargaining prices for supplies in eight regions On March 24, according to the news from Huazhao Equipment Network, the Xinxiang City Drugs and Medical Consumables Alliance Centralized Procurement Platform issued the "Notice on Online Quotations for the Centralized Procurement of Medical Consumables Alliance of Eight Cities (Counties) including Xinxiang City, Henan Province".
-
Huahai Pharmaceutical Sitagliptin Phosphate Tablets Received Acceptance from CDE
Time of Update: 2021-04-27
0 Chinese Drug Evaluation DatabaseAt present, the only companies approved for sitagliptin phosphate tablets in the domestic market are Merck and Dongyang Pharmaceutical, and Chia Tai Tianqing Pharmaceutical Group.
Sitagliptin phosphate tablets from 11 companies are under review and approval.
-
FDA concerns about the safety of Pfizer/Lilly's new painkiller tanezumab
Time of Update: 2021-04-27
”The US FDA added, “Although the two companies have proposed clinical risk mitigation strategies in the study, the risk of RPOA is still worrying, because a considerable number of patients with adverse events require total joint replacement.
-
Pfizer said an oral new crown treatment drug has entered clinical trials
Time of Update: 2021-04-27
On March 24th, 23rd local time in the United States, the pharmaceutical company Pfizer announced on its official website that the oral new crown treatment drug PF-07321332 has entered the phase 1b clinical trial phase.
This is the world's first oral new crown treatment drug to enter clinical trials.
-
6681 pharmaceutical companies were notified that multiple provinces have successively issued notices
Time of Update: 2021-04-27
According to the "Guiding Opinions of the National Medical Security Administration on Establishing a Medical Price and Recruitment Credit Evaluation System", the center organized platform-related pharmaceutical companies to submit the "Pharmaceutical Enterprise Price and Marketing Behavior Credit Commitment".
-
Eli Lilly's basal insulin BIF has a hypoglycemic effect comparable to Novo Nordisk insulin
Time of Update: 2021-04-27
CompilenewbornAccording to a phase 2 clinical trial (NCT03736785), a new once-a-week basal insulin injection has similar efficacy and safety compared with once-a-day basal insulin, and has a lower incidence of hypoglycemia.
-
A complete analysis of the development of Shanghai's hospital drug market in 2020
Time of Update: 2021-04-27
Figure 5 The growth rate of different therapeutic areas in the Shanghai hospital drug market in 2020 Medical Network, March 24th, this issue of HMAS medical institution market analysis system in-depth deconstruction of the Shanghai hospital drug market in 2020: under the influence of the epidemic and large-scale procurement, how will the hospital market at all levels and categories perform in 2020?
-
Tide Pharmaceuticals won the title of "Model of Capital Civilized Unit"
Time of Update: 2021-04-27
The picture above shows the list of pacesetters of civilized units in the capital of the Economic Development ZoneThe capital's spiritual civilization creation activity is held every three years and is an important honor in the field of the capital's spiritual civilization construction.
-
Yiling Pharmaceutical Dextromethorphan Hydrobromide Tablets Passed the Consistency Evaluation
Time of Update: 2021-04-27
On March 24, Yiling Pharmaceutical announced that it received the "Drug Supplementary Application Approval Notice" for dextromethorphan hydrobromide tablets approved and issued by the National Medical Products Administration.
At present, only 2 dextromethorphan hydrobromide tablets in China have passed the consistency evaluation (including the products approved by the company this time).
-
Macau suspends vaccination of mRNA COVID-19 vaccine today due to defective packaging
Time of Update: 2021-04-27
The Macao Coordinating Center for Coordination of New Coronavirus Infections said on the 24th that the Macao Health Bureau has received a written notice from Fosun Industrial (Hong Kong) Company, as it has recently noticed a number of mRNAs produced by Baintech Biopharmaceutical with batch number 210102.
-
AstraZeneca announces the latest phase 3 clinical results of the new crown vaccine
Time of Update: 2021-04-27
The Data Safety Monitoring Committee found no increased risk of thrombosis in 21,583 subjects who received at least one dose of the vaccine, and no CVST event was found in this clinical trial.
-
The final results of phase 3 clinical analysis of olaparib for ovarian cancer are released
Time of Update: 2021-04-27
Recently, "The Lancet-Oncology" published a double-blind, randomized, placebo-controlled phase 3 clinical trial of olaparib as maintenance treatment for patients with BRCA1/2 mutant platinum-sensitive recurrent ovarian cancer (SOLO2/ENGOT-Ov21) final analysis result.
-
Janssen's new RSV fusion protein inhibitor plans to be included in breakthrough treatment varieties
Time of Update: 2021-04-27
Public information shows that JNJ-53718678 is a new type of human RSV fusion protein inhibitor with the potential to treat respiratory syncytial virus infection.
Studies have found that the fusion glycoprotein (F) is essential for RSV to enter cells, which makes it an ideal target for researchers to develop RSV fusion protein inhibitors.
-
New drug Zegalogue for the treatment of severe hypoglycemia received FDA approval
Time of Update: 2021-04-27
Recently, the company announced that the US Food and Drug Administration (FDA) has approved Zegalogue (dasiglucagon) injection for the treatment of severe hypoglycemia in children and adults with diabetes aged 6 years and over.
-
7 new domestically produced Class 1 anti-ED drugs are coming, and Yangtze River sprints for the first time!
Time of Update: 2021-04-27
The fourth domestic anti-ED oral PDE-5 inhibitor strikes, Haisco will win the first imitation A few days ago, Sichuan Haisco entered the administrative examination and approval stage with imitation 3 types of avanafil tablets, which is expected to be approved in the near future.
